PFE - Deciphera completes enrollment in late-stage study of ripretinib in GIST patients

Deciphera Pharmaceuticals (DCPH) has completed the enrollment of ~426 gastrointestinal stromal tumor ((GIST)) patients in a Phase 3 clinical trial, INTRIGUE, evaluating Qinlock (ripretinib) in a second-line setting compared to Pfizer's (PFE) Sutent (sunitinib) .The primary endpoint is progression-free survival ((PFS)) up to month 30. Topline results should be available in H2 2021.The FDA OK'd ripretinib, a switch-control tyrosine kinase inhibitor, in May for fourth-line GIST.

For further details see:

Deciphera completes enrollment in late-stage study of ripretinib in GIST patients